Michael Graves was President and Chief Executive Officer of Paddock Laboratories, a developer, manufacturer and marketer of OTC and specialty brand and generic prescription products from 2007 to July 2011. Mr. Graves grew the sales of the company from $65 million to over $220 million prior to its acquisition by Perrigo for $540 million dollars. Prior to his position with Paddock Laboratories Mr. Graves was President of the Generic Division of Par Pharmaceutical, at which time, was the fifth largest marketer of generic products in the United States. Mr. Graves has also held executive positions at two of the country’s largest pharmaceutical distributors. Mr. Graves received a BS from the State University of New York, Buffalo and has over 18 years of diverse pharmaceutical experience.